Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nordic Nanovector ASA ( (DE:8NN) ) just unveiled an announcement.
Thor Medical ASA announced its interim results for the first half of 2025, highlighting significant progress in its commercial operations. The company has made a final investment decision on its first commercial-scale manufacturing facility, AlphaOne, and secured strategic agreements for raw materials and sales. Financially, Thor Medical reported a revenue of NOK 0.1 million and an EBITDA loss of NOK 23.1 million, but remains financially strong with substantial capital raised for AlphaOne. The construction of AlphaOne is underway, and the company is poised to capitalize on the growing market for alpha-emitting cancer therapies.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, focusing on alpha particle emitters derived from naturally occurring thorium. The company is known for its environmentally friendly and cost-efficient production process, which does not require nuclear reactors. Based in Oslo, Norway, Thor Medical is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Average Trading Volume: 2,249,035
Current Market Cap: NOK1.01B
For a thorough assessment of 8NN stock, go to TipRanks’ Stock Analysis page.